Publications for Stephen Seligman STEPHEN_SELIGMAN@NYMC.EDU
Bakhvalova, V. N., Chicherina, G. S., Potapova, O. F., Panov, V. V., Glupov, V. V., Potapov, M. A., . . . Seligman, S. J. (2016). Tick-borne encephalitis virus diversity in Ixodid ticks and small mammals in south-western Siberia, Russia. Vector Borne and Zoonotic Diseases, 16(8), 541-549. doi:10.1089/vbz.2015.1834
Clarke, D. K., Hendry, R. M., Singh, V., Rose, J. K., Seligman, S. J., Klug, B., . . . Brighton Collaboration Viral Vector Vaccines Safety Working Group. (2016). Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment. Vaccine, 34(51), 6597-6609. doi:10.1016/j.vaccine.2016.06.071
Condit, R. C., Williamson, A. L., Sheets, R., Seligman, S. J., Monath, T. P., Excler, J. L., . . . Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). (2016). Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains. Vaccine, 34(51), 6610-6616. doi:10.1016/j.vaccine.2016.04.060
Klug, B., Robertson, J. S., Condit, R. C., Seligman, S. J., Laderoute, M. P., Sheets, R., . . . Brighton Collaboration Viral Vaccine Vector Safety Working Group. (2016). Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis. Vaccine, 34(51), 6617-6625. doi:10.1016/j.vaccine.2016.02.015
Chen, R. T., Carbery, B., Mac, L., Berns, K. I., Chapman, L., Condit, R. C., . . . Seligman, S. J., (2015). The Brighton Collaboration Viral Vector vaccines Safety Working Group (V3SWG). Vaccine, 33(1), 73-75. doi:10.1016/j.vaccine.2014.09.035
Monath, T. P., Seligman, S. J., Robertson, J. S., Guy, B., Hayes, E. B., Condit, R. C., . . . Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) (2015). Live virus vaccines based on a yellow fever vaccine backbone: Standardized template with key considerations for a risk/benefit assessment. Vaccine, 33(1), 62-72. doi:10.1016/j.vaccine.2014.10.004
Casanova, J. L., Conley, M. E., Seligman, S. J., Abel, L., & Notarangelo, L. D. (2014). Guidelines for genetic studies in single patients: Lessons from primary immunodeficiencies. The Journal of Experimental Medicine, 211(11), 2137-2149. doi:10.1084/jem.20140520
Seligman, S. J. (2014). Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine, 32(44), 5769-5775. doi:10.1016/j.vaccine.2014.08.051
Seligman, S. J., Cohen, J. E., Itan, Y., Casanova, J. L., & Pezzullo, J. C. (2014). Defining risk groups to yellow fever vaccine-associated viscerotropic disease in the absence of denominator data. The American Journal of Tropical Medicine and Hygiene, 90(2), 267-271. doi:10.4269/ajtmh.13-0542
Seligman, S. J. (2013). Alternative mutational pathways to increased vancomycin resistance in MRSA. The Journal of Infectious Diseases, 208(11), 1925. doi:10.1093/infdis/jit516
